Hello IPCI board just came back from 9 week Holiday in Greece and was wondering what was the thought of IPCI in Europe and here is what I found.....Remember I had Google Translate the page so may have some off wording.
Biotech Investing today in the market here is the quarterly Curis (CRIS) and IntelliPharmaCeutics (IPCI). Here's what's new?
As you have seen is the long-awaited release of quarterly one of the most followed blog or IntelliPharmaCeutics International Inc. (IPCI). We will take advantage of budgetary data to see what's new, and I like it I would like to think out loud by writing spontaneously, in apnea, my remarks.
The fact that after the exit of the quarterly pricing will be brought in the values ??of the TMJ in fact it is not so much a surprise though at the moment the drop made ??us tremble . Some of you have taken advantage of to increase.
The actual sale of shares in the market were said and read in various network theories and figures, we finally have the numbers on which to reason. Indeed, the dilution was minimal. I had commented on the blog that I think this is positive news.
In November, 2013, Intellipharmaceutics Entered into an at-the-market offering program under Which it may, from time to time, sell up to 5,305,484 of Its common shares for up to an aggregate of $ 16.8 million (or longer available lesser amount as may be permitted under applicable securities laws and Regulations) on the NASDAQ or Otherwise, Which of 1,312,100 common shares of the ITS Have Been sold for net proceeds of $ 4,808,054 as of the date of this release.
The friend Lupo always very attentive and always follow the blog, rightly pointed out that with a phase III could probably starting in 2014 Rexista of this money are few. Even the friend Bazar always very critical of the company pointed out some items that he liked. All of us must be increasingly critical and always put in doubt what we read in the press releases of the companies in the portfolio that we have both in your watchlist, then we welcome your thoughts.
So to answer these repeat once more that a few occasions as announced by the company, this is going to pay for the development and all that there is' linked to the commercialization / marketing of the drug Rexista to a potential partner. If we account of this money collected from this issue ATM to which we must add the income already received from sales of Focalin XR, the company will allow a peaceful 2014.
Let us remember that the proceeds of Focalin are just at the beginning and every quarter we will from time to time as will cash. My theory that I announced after the announcement of the ATM is always the same. For those who have lost is this. According to me the ATM is a parachute. They could have put all of the outstanding shares as early as the following day, and as usual instead of the company has been made, for the moment, as little as possible . L 'ATM is not free but you pay the fees, the company is famous for being thrifty, and in any case by ATM sales and revenues should now be approximately $ 8M of which have yet to be added the proceeds from the sale of Focalin XR' January 1 until yesterday, and which will be paid quarterly, however.
We remember only for completeness of the data that the partner PAR has already paid on income of $ 3.1M from the date of approval or November 2013 to December 2013.
The question I have is this place on the ATM anyway? Where did all the actions? all in the portfolios of small investors? Maybe NO. In the days where there were larger volumes in fact there have been some heavy exchanges of shares, some large purchases may suggest that someone may have increased its position in the market.
After a long discussion of the number of shares outstanding on the blog we now have more data available:
As of November 30, 2013, the directors and executive officers of the Company as a group owned, Directly and Indirectly, or exercise control or direction over 6,166,219 common shares, representing Approximately 28.8% of the issued and outstanding common shares of the Company.
Our principal shareholders, Drs. Amina and Isa Odidi, our President and Chief Operating Officer and our Chairman and Chief Executive Officer, respectively, and Odidi Holdings Inc., a privately-held company controlled by Drs. Amina and Isa Odidi, Directly and Indirectly owned 5,997,751 common shares, representing Approximately 28.0% of our issued and outstanding common shares of the Company. As a result, the principal shareholders have the ability to exercise significant influence over all matters Submitted to our shareholders for approval Whether subject to approval by a Majority of holders of our common shares or subject to a class vote or special resolution Requiring the approval of 66 % of the votes cast by holders of our common shares, in person or by proxy.
So 6,166,219 shares ie 28.8% belong to their spouses Odidi, and 5,997,751 shares ie 28% of the shares are owned by the Odidi Holdings. This means that 56.8% of the shares are in the hands of the founders of the company. If we add up the shares of the holding company and other units of Matthew and George are not many shares outstanding. haha!
Shifting our attention on the part of the quarterly business and clinical development, we read some considerations of the company.
Let's see a few appointments for 2014: I will start a second phase of Regabatin ™ XR drug bioequivalent drug blockbuster Lyrica® but in this new role as well as being bioequivalent, will have the task to allow patients to take fewer doses, and as a result will improve the relationship of the patient with the drug and potentially result in improved efficacy. How did it succeed? '... The answer is in the patents filed by the company.
"We plan to initiate additional Phase I clinical trials in 2014".
Going forward I did not like the silence from the company regarding the Rexista. Do not expect them the announcement of a possible partner yesterday, but additional data from phase 1 promised by the end of 2013 have not yet arrived. Hopefully this waiting is rewarded by announcing maybe both, of course that's just my hope.
We may be close enough to the filing of yet another ANDA. The generic drug in clinical stage is the Coreg CR by GlaxoSmithKline which utilized technology company that I pointed out long ago that Flamel Technologies.
Carvedilol is indicated for the treatment of essential hypertension. Doing a quick search the drug should be covered by a patent until 2015, but have already started Lawsuit in particular I found that Flamel with Lupin Limited for infringement of patent 6,022,562, which is the 2011 is not the only company that has filed ANDA as often happens. The drug continues to have a good market even after many years.
To conclude on the basis of the budget just seen and based on the pipeline that we now know by heart, 2014 looks like a year that could bring satisfaction to the company. I am always of the opinion that it is a title, between small, very solid.
AI
